Ico Therapeutics (ICOTF) 0.0250 $ICOTF
CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Marketwired - Tue Dec 09, 10:13AM CST
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
CNW Group - Fri Nov 28, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" .
ICO.VN: 0.035 (unch)
Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference
PR Newswire - Tue Nov 11, 7:00AM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced that Dr. Daniel Teper, Chairman & CEO, will discuss personalized medicine at a panel taking place on Thursday, November 13, 2014, at 9:45 a.m.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS
PR Newswire - Tue Nov 04, 6:00AM CST
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today announced that presentations regarding the company's Oral Amphotericin B drug candidate will be made at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The event takes place at the San Diego Convention Center November 2 - 6.
ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program
CNW Group - Wed Oct 22, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today announced next steps for its Oral Amphotericin B program. The company recently announced positive findings from its in vitro work involving samples from HIV/AIDS patients exposed to HAART therapy. iCo now plans to complete pre clinical studies and regulatory filings to move forward with an initial Phase 1A clinical trial, utilizing approximately $700,000 of funding and technological advice from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), under the Canadian HIV Technology Development (CHTD) Program.
ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 29, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" .
ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
CNW Group - Tue Aug 19, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp 
drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy.
ICO.VN: 0.035 (unch)
iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity.
ICO.VN: 0.035 (unch)
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company" appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:
ICO.VN: 0.035 (unch)
CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Marketwired - Tue Dec 09, 10:13AM CST
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
CNW Group - Fri Nov 28, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" . ICO.VN: 0.035 (unch)
Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference
PR Newswire - Tue Nov 11, 7:00AM CST
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced that Dr. Daniel Teper, Chairman & CEO, will discuss personalized medicine at a panel taking place on Thursday, November 13, 2014, at 9:45 a.m.
ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS
PR Newswire - Tue Nov 04, 6:00AM CST
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today announced that presentations regarding the company's Oral Amphotericin B drug candidate will be made at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The event takes place at the San Diego Convention Center November 2 - 6. ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program
CNW Group - Wed Oct 22, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today announced next steps for its Oral Amphotericin B program. The company recently announced positive findings from its in vitro work involving samples from HIV/AIDS patients exposed to HAART therapy. iCo now plans to complete pre clinical studies and regulatory filings to move forward with an initial Phase 1A clinical trial, utilizing approximately $700,000 of funding and technological advice from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), under the Canadian HIV Technology Development (CHTD) Program. ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Second Quarter 2014 Financial Results
PR Newswire - Fri Aug 29, 6:00AM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS" . ICO.VN: 0.035 (unch)
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results
CNW Group - Tue Aug 19, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported results of its Oral Amphotericin B (Oral Amp drug candidate targeting latent HIV reservoirs. The study, conducted by ImmuneCarta®, the immune monitoring business unit of Caprion, evaluated in vitro effectiveness of Oral Amp B in reactivating latent HIV viral reservoirs which remain present in individuals despite intensive treatment with antiretroviral therapy. ICO.VN: 0.035 (unch)
iCo Therapeutics Inc. - No Material Change
CNW Group - Tue Jul 15, 12:29PM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), at the request of IIROC, confirms that there is no material change that would account for the recent increase in market activity. ICO.VN: 0.035 (unch)
Immune Appoints Cameron Durrant, MD, MBA to Board of Directors
GlobeNewswire - Mon Jul 14, 2:14AM CDT
Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) ("Immune" or "the Company"
appointed Dr. Cameron Durrant as new independent director. Dr. Durant becomes a Member of the Compensation Committee and the R&D Committee. ICO.VN: 0.035 (unch), IMNP: 1.87 (-0.03)
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders
PR Newswire - Mon Jun 30, 6:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that all nominees listed in the management information circular datedMay 28, 2014were elected as directors at its 2014 Annual Meeting of Shareholders, held onFriday, June 27, 2014. On a vote by ballot, the following five nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows: ICO.VN: 0.035 (unch)
